Cannabis Law Report

AUGUST 18, 2022

The firm’s deep expertise in pharmaceutical sciences, FDA regulatory compliance and pharmaceutical product liability litigation and risk management enables it to address complex legal hurdles faced by stakeholders seeking to research, develop, invest in and bring-to-market psychedelic therapies. BUFFALO, N.Y. , Aug. Tweet this.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Veriheal

JUNE 22, 2021

Over the next decade, the United States could stand to see an explosion in the research of cannabinoid therapies. As the medical understanding of cannabinoid therapies and their actions become more advanced, hopefully, the United States federal government will be able to keep up and adjust laws pertaining to cannabis accordingly.

DEA 60

DEA Access Therapy Cannabinoids 60

SpeedWeed

MARCH 11, 2021

“The case is about seeking to ensure that patients with serious, life-threatening illness are able to realize the promise of state and federal Right to Try laws and access psilocybin for therapeutic purposes.”. At that point, the team decided to sue the DEA to change its decision. “I We don’t have much of an explanation at all.”

DEA 52

DEA Patients Access Advocacy 52

Cannabis Law Report

JULY 9, 2021

The state of the law on psychedelic substances is in flux. The use of psychedelic substances to treat mental illness and physical disorders is known as “psychedelic therapy.” Psychedelic therapy is not a fringe phenomenon. Some of the most promising substances, and the law applicable to each, are outlined below: Psilocybin.

Law 105

Law Therapy Clinical Trials Research and Development 105

Veriheal

NOVEMBER 11, 2023

According to the United States Drug Enforcement Administration (DEA), Schedule One drugs are “drugs with no currently accepted medical use and a high potential for abuse.” Simply put, in the eyes of federal law, cannabis is illegal. According to Federal law, cannabis use is illegal. Is Medical Cannabis Legal? No, they can’t.

Law 62

Law Chronic Pain Conditions Legislation 62

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. . Most recently the FDA awarded MMJ International Holdings ? .

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

FEBRUARY 28, 2022

Moreover, because Indigenous communities pioneered many aspects of modern psychedelic therapies, their patenting by Western corporations may promote biopiracy, the exploitation of Indigenous knowledge without compensation. MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study , 27 NATURE MED.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

NOVEMBER 2, 2022

Drug Enforcement Administration and the legal team representing terminally ill patients petitioning for access to psilocybin-assisted therapy. In late September, the DEA denied an official petition requesting that the agency look into rescheduling psilocybin from Schedule I to Schedule II.

Microdosing 52

Microdosing DEA Therapy Access 52

Cannabis Law Report

MAY 10, 2022

Activists staged a demonstration outside of the Drug Enforcement Administration (DEA) headquarters in Virginia on Monday, demanding that the agency allow terminally ill patients to access psilocybin therapy. Marijuana Moment reports. DeaOutoftheway @RTTpsilocybin pic.twitter.com/1NJWt2cJWn. aeidinger) May 9, 2022.

DEA 52

DEA Therapy Access Patients 52

Cannabis Law Report

MAY 29, 2022

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. DEA and the Controlled Substances Act.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Canna Law Blog

AUGUST 25, 2020

The Food and Drug Administration (FDA) already has granted MAPS “breakthrough therapy” approval based on earlier trials. The drug caught DEA’s attention when recreational use proliferated. Fortunately, by criminalizing MDMA, DEA was able to stamp out its use entirely, as it did with cannabis and other hazardous schedule I drugs.

DEA 88

DEA Therapy Decriminalization Pharmaceutical 88

Veriheal

APRIL 11, 2022

federal law , it has not yet been used in any commonly prescribed medicines. The company initiated the first legal transfer (as deemed by federal law) to the U.S. Drug Enforcement Agency (DEA). federal law. federal law, from which point, informed choices can be made about the use of cannabis and cannabinoids.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Canna Law Blog

AUGUST 25, 2020

The Food and Drug Administration (FDA) already has granted MAPS “breakthrough therapy” approval based on earlier trials. The drug caught DEA’s attention when recreational use proliferated. Fortunately, by criminalizing MDMA, DEA was able to stamp out its use entirely, as it did with cannabis and other hazardous schedule I drugs.

DEA 84

DEA Therapy Decriminalization Pharmaceutical 84

NewsMunchies

NOVEMBER 12, 2021

Psychedelic mushrooms are not legal, per se , but cities and states have decriminalized the plant, meaning law enforcement will not arrest those in possession of it. State-level ballot measures may further broaden the legal circumstances and settings in which psychedelics can be used for mental health therapy.

Clinical Trials 90

Clinical Trials Therapy Decriminalization DEA 90

Canna Law Blog

JULY 17, 2020

This is being done in violation of international law and the quality is famously poor, in any case (it’s more like hemp). A: OK, after your get the IRB approval letter, you need permission from the Drug Enforcement Agency (DEA)– Q: Hold on. Why do we need to involve law enforcement? How do I get DEA permission?

DEA 84

DEA Research and Development Therapy Banking 84

Cannabis Law Report

OCTOBER 6, 2021

Bright Green will be operating under a Memorandum of Agreement with the Drug Enforcement Administration (DEA). Today launches a new era in plant-based therapy research. According to a press release by the company, they intend for the facility to be part of a larger national market for cannabis research and products.

DEA 52

DEA Therapy Environment Agriculture 52

Veriheal

AUGUST 24, 2022

Now, a psychedelic-focused bill aimed at reforming laws surrounding psychedelics further in the state has successfully qualified for the November ballot. In May 2022, Connecticut’s governor signed a budget bill that included a provision for the implementation of psychedelic-assisted therapy treatment centers. city to do so.

Legalization 109

Legalization Decriminalization Medicine Research and Development 109

Veriheal

DECEMBER 27, 2022

Researchers have taken a big step in understanding the connection between using psychedelics and feeling connected to nature in a study published in the journal Drug Science, Policy, and Law on Oct. Scientists Hope New Findings Will Help Expand Research on Psychedelic Therapy.

Research and Development 97

Research and Development Therapy Consumption DEA 97

Canna Law Blog

OCTOBER 15, 2020

Oregon Psychedelics: Petition to Legalize Psilocybin for Therapy Moves Forward. Psilocybin remains a Schedule 1 drug, meaning the DEA says it has a high likelihood of abuse and no accepted medical use – just like marijuana. law enforcement. For our coverage of Oregon’s Measure 109, see: Oregon 2020 Election: Vote Yes!

DEA 91

DEA Therapy Decriminalization Cultivation 91

Cannabis Law Report

APRIL 21, 2022

MDMA is a promising psychedelic compound, currently placed by the Drug Enforcement Administration (DEA) in Schedule I of the Controlled Substances Act, that has been produced for legal research in small batches by certified laboratories. The safety and efficacy of MDMA-assisted therapy is currently under investigation. MEDIA CONTACT .

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

NOVEMBER 20, 2021

The draft rules were developed in accordance with the state’s new law on medical cannabis, which was approved earlier this year by the state Legislature and signed into law by the governor. registrations with the DEA, the Alabama Medical Cannabis Patient Registry, and the Alabama Prescription Drug Monitoring Program.

Patients 52

Patients DEA Dispensary Conditions 52

Cannabis Law Report

MAY 31, 2022

Two approaches apply to commercial operations—the traditional medical path and the emerging non-medical state-regulated path, while the other two paths are better seen as non-commercial—underground therapy and religious use. Breakthrough Therapy status obtained by COMPASS Pathways and Usona Institute. Breakthrough Therapy.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

SpeedWeed

AUGUST 16, 2021

And we’re gonna have to change therapies to try to win this battle. He owned and operated Eddy’s Medicinal Gardens and Multi-Denominational Chapel of Cannabis and Rastafari, which was raided by Drug Enforcement Administration (DEA) officials on August 18, 2004—the 17th anniversary of which is just days away. The presiding U.S.

DEA 52

DEA Patients Therapy Cannabis 52

Cannabis Law Report

MARCH 2, 2020

Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to Compass Pathways ‘ psilocybin therapy for treatment-resistant depression. A few months later, the agency awarded BTD for Usona Institute ‘s psilocybin therapy for major depressive disorder. Then, something strange happened.

Medicine 59

Medicine Therapy DEA Pharmaceutical 59

CannaMD

AUGUST 8, 2020

Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential. However, there are a number of restrictions. CBD Scheduling Rule Change.

CBD 100

CBD DEA Research and Development Hemp 100

Cannabis Law Report

OCTOBER 5, 2021

“This shows that combination of psilocybin and music has a strong emotional effect, and we believe that this will be important for the therapeutic application of psychedelics if they are approved for clinical use,” said lead researcher Dea Siggaard Stenbæk , Associate Professor University of Copenhagen.

Clinical Trials 52

Clinical Trials Research and Development DEA Therapy 52

CannaMD

SEPTEMBER 10, 2020

Is it safe to continue cannabis-based therapies during pregnancy? This creates a somewhat confusing landscape for mothers who might benefit from cannabis-based therapies, but are also concerned for the safety of their child and the very real possibility of institutional intervention when marijuana use during pregnancy is documented.

Marijuana 60

Marijuana Therapy Data THC 60

Veriheal

JUNE 29, 2021

In the last 100 years, many of the plant therapies that were embraced in history were outlawed by governments around the world and replaced by lab-made synthetic drugs we label medicine. Today there are 41 states that have enacted some form of a Right to Try or RTT laws. Introducing the Right to Try Act. A Push by Patients.

Therapy 56

Therapy DEA Patients Clinical Trials 56

Cannabis Law Report

AUGUST 23, 2021

Nonetheless, laws applicable to the practice of medicine that may impact speech, such as laws that might limit a vet’s ability to recommend CBD products, will generally pass constitutional muster. She acknowledged that “FDA is considering the possibility of new legal pathways for CBD products.”. Final Thoughts.

Pets 105

Pets Hemp CBD Food 105

Cannabis Law Report

AUGUST 12, 2022

Drug policy topics have become a consistent feature of the Austin-based event in recent years as more states have legalized cannabis and moved to reform laws around psychedelics like psilocybin locally and at the state level. Obtaining DEA License to Grow Psilocybin Mushrooms. Here are some psychedelics panel options: .

Research and Development 52

Research and Development Events Topical Policy 52

Cannabis Law Report

DECEMBER 21, 2021

Numinus also made important alliances in 2021, particularly with the Multidisciplinary Association for Psychedelic Studies (MAPS) on its compassionate access trial for MDMA-assisted therapy. It was officially listed on the NYSE in August and granted a DEA schedule I manufacturing license in November. Cybin (NYSE: CYBN).

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

MedicalJane

JUNE 29, 2018

Doctors may not prescribe cannabis products to patients because marijuana is currently listed as an example of a Schedule I drug according to the DEA. State laws will set the guidelines for qualifying a practitioner. Depending on where you live, a medical practitioner will either certify or recommend the use of cannabis.

Patients 83

Patients Legalization Conditions Treatment 83

Cannabis Law Report

JULY 1, 2021

From their blog… Q&A with Mason Marks on New Psychedelics Law and Regulation Initiative. On June 30th, the Petrie-Flom Center announced the launch of a three-year research initiative , the Project on Psychedelics Law and Regulation (POPLAR) , which is supported by a generous grant from the Saisei Foundation.

Law 105

Law Research and Development Therapy DEA 105

Cannabis Law Report

JULY 27, 2021

As part of Project Change Lives, Clever Leaves has committed to supplying up to 250,000 bottles of pharmaceutical-grade cannabis oils or approximately 5 tons of medical cannabis flower that will help research institutions develop new therapies. For more information, please visit [link] and follow us on LinkedIn.

Research and Development 98

Research and Development Pharmaceutical Sativa Extraction 98

Canna Law Blog

NOVEMBER 6, 2021

But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Research was permitted in the mid-20th century, until the law stepped in. Psilocybin, a compound produced by many species of fungi, is one of the most well-studied psychedelics.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Canna Law Blog

MARCH 4, 2020

In an even larger trend, the health care provider community seems to be exploring various alternative therapies and emerging medicines to improve quality of care. The FDA doesn’t have any regulations on point for the control and oversight of ketamine clinics when it comes to infusion therapy and the states don’t really either.

Therapy 88

Therapy Legalization Chronic Pain DEA 88

Canna Law Blog

MARCH 4, 2020

In an even larger trend, the health care provider community seems to be exploring various alternative therapies and emerging medicines to improve quality of care. The FDA doesn’t have any regulations on point for the control and oversight of ketamine clinics when it comes to infusion therapy and the states don’t really either.

Legalization 52

Legalization Therapy Chronic Pain DEA 52